MOMENT study of METex14 NSCLC patients
Part of Cancer clinical trials.
This registry study enrolls people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called METex14 skipping. It aims to learn about how these cancers are treated in real life, which may help future care decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign the informed consent form (ICF) to join
- You have advanced NSCLC in stages IIIB, IIIC, or IV
- Your tumor test must confirm a METex14 skipping change using an approved lab test
- You are starting or already receiving medicines that treat cancer throughout the body (systemic therapy)
- You cannot be enrolled in another clinical trial at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information from people with cancer that has spread who are receiving radiation therapy as part of their usual care. By joining, you help researchers learn more about how radiation works in this setting.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.